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Abstract: The relationship between the multidrug-resistant (MDR) phenotype and biofilm-forming
capacity has been a topic of extensive interest among biomedical scientists, as these two factors may
have significant influence on the outcomes of infections. The aim of the present study was to establish
a possible relationship between biofilm-forming capacity and the antibiotic-resistant phenotype in
clinical Acinetobacter baumannii (A. baumannii) isolates. A total of n = 309 isolates were included in this
study. Antimicrobial susceptibility testing and the phenotypic detection of resistance determinants
were carried out. The capacity of isolates to produce biofilms was assessed using a crystal violet
microtiter-plate-based method. Resistance rates were highest for ciprofloxacin (71.19%; n = 220),
levofloxacin (n = 68.61%; n = 212), and trimethoprim-sulfamethoxazole (n = 66.02%; n = 209); 42.72%
(n = 132) of isolates were classified as MDR; 22.65% (n = 70) of tested isolates were positive in the
modified Hodge-test; the overexpression of efflux pumps had significant effects on the susceptibilities
of meropenem, gentamicin, and ciprofloxacin in 14.24% (n = 44), 6.05% (n = 19), and 27.51% (n = 85),
respectively; 9.39% (n = 29), 12.29% (n = 38), 22.97% (n = 71), and 55.35% (n = 170) of isolates were
non-biofilm-producing and weak, moderate, and strong biofilm producers, respectively. A numerical,
but statistically not significant, difference was identified between the MDR and non-MDR isolates
regarding their biofilm-forming capacity (MDR: 0.495 ± 0.309 vs. non-MDR: 0.545 ± 0.283; p = 0.072),
and no association was seen between resistance to individual antibiotics and biofilm formation.
Based on numerical trends, MER-resistant isolates were the strongest biofilm producers (p = 0.067).
Our study emphasizes the need for additional experiments to assess the role biofilms have in the
pathogenesis of A. baumannii infections.
Keywords: Acinetobacter baumannii; antibiotic resistance; multidrug resistance; MDR; biofilm; crystal
violet; phenotypic assay
1. Introduction
Due to the growing number of patients affected by invasive medical interventions and
immunosuppression, the prevalence and disease burden of infections caused by nonfer-
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menting Gram-negative bacteria (NGFNBs; including Pseudomonas aeruginosa, Acinetobacter
spp., and Stenotrophomonas maltophilia) have also increased considerably [1]. The genus
Acinetobacter is an oxidase-negative coccobacillus, consisting of >40 genospecies, among
which the Acinetobacter baumannii-calcoaceticus complex is the most clinically relevant [2].
A. baumannii is an important opportunistic pathogen in nosocomial infections, which—although
traditionally considered a low-grade pathogen—has been implicated in a wide array of
infectious syndromes, including bacteremia, pneumonia (especially ventilator-associated
pneumonia (VAP)), urinary tract infections, and eye and wound infections, affecting
patients with immunosuppression, severe underlying conditions, or patients in critical
condition (treated in Intensive Care Units (ICUs)) [3–6]. Patients experiencing prolonged
(≥90 days) hospitalization and previous antimicrobial therapy are particularly at risk [7].
The reported mortality rate of invasive A. baumannii infections is considerably high, ranging
between 23% and 68% and between 0% and 64% for nosocomial and community-associated
infections, respectively [8]. In a recent meta-analysis of 114 studies, the estimated mortality
of A. baumannii VAP has been reported at 42.6% (95% CI, 37.2–48.1%), while other studies
have shown that the mortality rate of the A. baumannii bacteremia in ICUs was between
37% and 52%, while for VAP, this figure might be as high as 84% [9].
Since the 2000s, the emergence of multidrug-resistant (MDR) and extensively drug-
resistant (XDR) strains of A. baumannii has become a critical concern for healthcare pro-
fessionals worldwide, with an alarmingly low number of antibiotics left useful for their
treatment [10]. The previously mentioned meta-analysis reported the prevalence of MDR
A. baumannii in nosocomial pneumonia at 79.9% (95% CI, 73.9–85.4%) in some regions
(Central America, Latin America, and the Caribbean), where all isolates are now considered
MDR [9]. In addition to their nonsusceptibility to many commonly used antimicrobials,
Acinetobacter spp. are characterized by a considerable genomic plasticity, and a tremendous
capacity to uptake novel resistance determinants (via plasmids, transposons, and integrons,
accumulating them in large genomic islands in their chromosome), leading to infections
where they are no longer a safe and effective drug for treatment [11]. Carbapenem-resistant
A. baumannii (CR-AB) has been designated as a “critical priority” pathogen for the devel-
opment of novel antibiotics and anti-infectives, according to the report published by the
World Health Organization (WHO) [12].
Biofilms are complex assemblages of bacteria and an external matrix material, consist-
ing of exopolysaccharide (EPS) and other carbohydrates, proteins, lipids, environmental
DNA (eDNA), ions, and water [13,14]. Biofilms allow for a protective form of growth and
metabolic inactivity for microorganisms, providing a safe haven against environmental
stressors (sheer forces, heat and drying damage), attacks of the immune system (phago-
cytes, complement), disinfectants, and antimicrobials [15]. In fact, bacteria embedded in
deeper layers of the biofilm seldom come into contact with antibiotics, due to the inability
of these drugs to adequately penetrate into its deeper layers; this results in 10–1000-fold
higher minimum inhibitory concentration (MIC) values, compared to the ones observed for
planktonic cells [16]. The biofilm-forming capacity of A. baumannii largely contributes to its
success as a nosocomial pathogen, as it allows for survival within hospital environments
(e.g., taps and fluid containers) and on vascular catheters or other implantable devices [17].
It has been described that A. baumannii may survive for 4–5 months on abiotic surfaces,
while so-called “hypervirulent” forms of A. baumannii were also associated with strong
biofilm production [16,17]. The relationship between the antimicrobial-resistant phenotype
and the biofilm-forming capacity has been a topic of extensive interest among biomedical
scientists, as these two factors may have significant influence on the outcomes of infec-
tions [18,19]. In addition, there have been studies showing that nonlethal concentrations
of antibiotics induced biofilm production in various Gram-positive and Gram-negative
bacteria, suggesting a common response to overcome external stressors [20]. The aim of the
present study was to establish a possible relationship between biofilm-forming capacity
and the antibiotic-resistant phenotype in clinical A. baumannii isolates.
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2. Materials and Methods
2.1. Collection of Isolates
A total of three hundred and nine (n = 309) A. baumannii isolates were included in this
study, which were kindly provided from the strain collections of a Hungarian and Italian
tertiary-care hospital. The study used a cross-sectional design, with microorganisms that
were isolated between 1 January 2019 and 1 January 2020, originating from various types of
clinical specimens, being randomly selected to be included in our experiments. During the
study, A. baumannii clinical isolate no. 59738 (MDR isolate, weak biofilm producer) and A.
baumannii ATCC 19606 (susceptible isolate, strong biofilm producer) were used as control
strains (the latter was obtained from the American Type Culture Collection, Manassas, VI,
USA) [21]. Stock cultures were stored at −80 ◦C in a cryopreservation medium (700 µL of
trypticase soy broth + 300 µL of 50% glycerol) until use.
2.2. Re-Identification of Isolates
All isolates included in our study were re-identified as A. baumannii before further
experiments. Re-identification of isolates was carried out using matrix-assisted laser
desorption/ionization–time-of-flight mass spectrometry (MALDI–TOF MS; Bruker Dal-
tonics, Bremen, Germany); to perform the MALDI–TOF assay, bacterial cells from fresh
overnight cultures were transferred to a stainless-steel target. An on-target extraction was
performed by adding 1 µL of 70% formic acid prior to the matrix. After drying at room
temperature, the cells were covered with 1 µL of matrix (α-cyano-4-hydroxy cinnamic acid
in 50% acetonitrile/2.5% trifluoro-acetic acid; Bruker Daltonics, Bremen, Germany). Mass
spectrometry analyses were performed by a MicroFlex MALDI Biotyper (Bruker Daltonics,
Bremen, Germany) in positive linear mode across the m/z range from 2 to 20 kDa; for
each spectrum, 240 laser shots at 60 Hz in groups of 40 shots per sampling area were col-
lected [22]. For analyses of spectra, the MALDI Biotyper RTC 3.1 software and the MALDI
Biotyper Library 3.1 (Bruker Daltonics. Bremen, Germany) were utilized. After analysis,
a log(score) value was assigned to all isolates, indicating the reliability of MALDI–TOF
MS identification. The log(score) values were evaluated as follows: a log(score) <1.69
showed unreliable identification, 1.70–1.99 corresponded to probable genus-level identifi-
cation, 2.00–2.29 corresponded to reliable genus-level identification, while a score ≥2.30
corresponded to reliable species-level identification [23].
2.3. Antimicrobial Susceptibility Testing and Resistotyping
Antimicrobial susceptibility testing for respective isolates was carried out using
the Kirby–Bauer disk diffusion method (Oxoid, Basingstoke, UK), and in subsequent
experiments (when relevant) with E-tests (Liofilchem, Roseto degli Abruzzi, Italy) on
Mueller-Hinton agar (MHA) (bioMérieux, Marcy-l’Étoile, France) plates in the case of
imipenem (IMI; 10 µg), meropenem (MER; 10 µg), ciprofloxacin (CIP; 5 µg), levofloxacin
(LEV; 5 µg), trimethoprim-sulfamethoxazole (SXT; 23.75/1.25 µg), gentamicin (GEN; 10 µg),
and amikacin (AMI; 30 µg). Tigecycline (TIG) susceptibility was performed using E-tests
on MHA, while colistin (COL) susceptibility was performed using the broth microdilution
method in cation-adjusted Mueller-Hinton broth (MERLIN Diagnostika GmbH, Bremen,
Germany). The isolates were grouped into distinct resistotypes based on the presence
of phenotypic resistance to relevant antimicrobials [24]. Interpretation of the results was
based on the recommendations of the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) relevant at the time of isolation, with the exception of TIG, where the
U.S. Food and Drug Administration (FDA) breakpoint (resistance of MIC > 4 mg/L) was
applied [25,26]. Intermediate results were grouped with and reported as resistant [22]. Clas-
sification of the isolates as (MDR; resistance to at least one agent in ≥3 antibiotic groups)
was based on Magiorakos et al. [27]; in subsequent analyses, isolates were divided into
non-MDR and MDR. A multiple-antibiotic-resistance (MAR) index—ranging between 0
and 1—was calculated by dividing the total number of detected resistance to antimicrobials
for each isolate by the total number of tested antimicrobials [24].
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2.4. Phenotypic Detection of Carbapenemase and Metallo-β-Lactamase Production
To establish carbapenemase production in the A. baummanni included in the study, the
isolates were subjected to the modified Hodge (cloverleaf) test, as previously described [28].
In the assay, MER disks (10 µg; Oxoid, Basingstoke, UK) were utilized and Escherichia
coli ATCC 25922 was used as an indicator organism. Metallo-β-lactamase (MBL) pro-
duction was tested using the imipenem/EDTA combined disk test (CDT), as described
previously [29]. In preparation to this assay, imipenem/EDTA disks were prepared by
adding 750 µg of a sterile 0.5 M EDTA solution to a 10 µg imipenem disk, and then disks
were dried in a 37 ◦C incubator. Disks containing EDTA alone served as a negative con-
trol. The isolate was considered positive for MBLs if the inhibition zone diameter of the
imipenem/EDTA disk increased by ≥7 mm compared to the imipenem disk alone [28].
2.5. Phenotypic Detection of Bacterial Efflux Pumps Contributing to the MDR Phenotype
To establish the effects of the overexpression of resistance-nodulation-division (RND)
efflux pumps on the susceptibility of tested antimicrobials, a phenylalanine-arginine β-
naphthylamide (PAβN) plate-based assay was performed, as described by Salehi et al. [30].
During the experiments, the concentration of PAβN (Sigma-Aldrich, St. Louis, MO,
USA)—a compound with well-known efflux pump inhibitory activity—was 40 µg/mL in
the agar base, while CIP, GEN, and MER were selected as test antimicrobials; a four-fold
decrease in the MICs (determined by E-tests; Liofilchem, Roseto degli Abruzzi, Italy) of the
antimicrobials in the presence of PAβN, compared to the MIC values without the inhibitor,
was considered as positivity for efflux pump overexpression [30].
2.6. Biofilm Formation Assay
The capacity of respective A. baumannii isolates to produce biofilms was assessed using
a microtiter-plate-based method previously described by Ramos-Vivas et al. [31]. In brief,
fresh A. baumannii cultures (grown on Luria-Bertani (LB) agar) were inoculated into 5 mL
of Luria-Bertani (LB) broth and incubated overnight at 37 ◦C. The following day, 180 µL of
LB broth and 20 µL of A. baumannii suspension (set at 106 CFU/mL) were measured onto
96-well flat-bottomed microtiter plates, to a final volume of 200 µL, and incubated for 24 h
at 37 ◦C. After the incubation period, the supernatants were discarded and the wells were
washed three times using 200 µL of phosphate-buffered saline (PBS; pH at 7.2), to remove
planktonic cells, which may interfere with the interpretation of the results. After washing,
the wells were fixed with 250 µL of methanol (Sigma-Aldrich, St. Louis, MO, USA) for
10 min and stained with a 1.0% crystal violet (CV; Sigma-Aldrich, St. Louis, MO, USA) so-
lution for 15 min. Subsequently, the CV solution was discarded, and the wells were washed
three times with purified water, to remove excess stains. The contents of the wells were
re-suspended in 250 µL of 33% V/V% glacial acetic acid (Sigma-Aldrich, St. Louis, MO,
USA), and the absorbance at 570 nm (OD570) was measured using a microtiter plate reader.
All experiments were carried out in triplicate. The OD570 values of the measurements were
recorded as the mean ± standard deviation (SD). The interpretation of the results was
carried out based on the recommendations of Stepanovic et al. [32], namely, a cut-off value
of optical density (ODc) was calculated using the following formula: ODc = average OD of
the negative control + (3 × standard deviations of negative control). Subsequently, isolates
were classified into the following categories, based on their OD570 measurements: strong
biofilm producer (OD > 4 × ODc); medium biofilm producer (4 × ODc ≥ OD > 2 × ODc);
weak biofilm producer (2 × ODc ≥ OD > ODc); and nonbiofilm producer (OD ≤ ODc) [32].
2.7. Statistical Analysis
Descriptive statistical analysis (including means with ranges and percentages to char-
acterize data) was performed using Microsoft Excel 2013 (Redmond, WA, USA, Microsoft
Corp.). The normality of variables was tested using the Kolmogorov–Smirnov test. Inde-
pendent sample t-tests were performed to compare measurements of OD570 (for biofilm
production) between susceptible/resistant isolates to individual antibiotics, and among
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MDR and non-MDR A. baumannii isolates, respectively. Comparisons of groups (OD570
values for isolates resistant to respective antibiotics) were made by one-way analysis of
variance (ANOVA) with Tukey’s post hoc tests. Statistical analyses were performed with
SPSS software version 22 (IBM Corp., New York, NY, USA).
2.8. Ethical Considerations
The study was conducted in accordance with the Declaration of Helsinki and national
and institutional ethical standards. Ethical approval for the study protocol was obtained
from the Human Institutional and Regional Biomedical Research Ethics Committee, Uni-
versity of Szeged (registration number: 140/2021-SZTE [5019]).
3. Results
3.1. Antibiotic Susceptibility of Isolates Included in the Study
After re-identification with MALDI-TOF MS, all three hundred and nine (n = 309)
isolates were verified as A. baumannii, and thus, they were included in the subsequent
experiments. The antimicrobial resistance levels of the A. baumannii isolates included in
the study were the following (in decreasing order): CIP 71.19% (n = 220), LEV 68.61%
(n = 212), SXT 66.02% (n = 209), GEN 60.84% (n = 188), IMI 52.75% (n = 163), MER 51.46%
(n = 159), AMI 38.51% (n = 119), TIG 38.51% (n = 44; MIC > 4 mg/L), and COL 2.27% (n = 7;
MIC > 2 mg/L); overall, 42.72% (n = 132) of the isolates were classified as MDR, based on
the criteria of Magiorakos et al. The distribution of the various resistotypes detected among
A. baumannii isolates is presented in Table 1: twenty-one (I-XXI) different resistotypes were
identified, with the most numerous being resistotype XVIII (resistant to CIP, LEV, IMI,
MER, GEN, AMI, and SXT; 15.21%), XIV (resistant to CIP, LEV, GEN, AMI, and SXT; 9.40%),
and IV (resistant to GEN and SXT; 9.06%).
Table 1. Resistotype distribution and MAR indices of respective isolates.
Resistotypes Resistance Pattern MAR Index MDR Status * Ratio of Isolates(n, %)
I CIP 0.111
non-MDR (57.28%; n = 177)
9 (2.91%)
II LEV 0.111 10 (3.24%)
III SXT 0.111 20 (6.47%)
IV GEN, SXT 0.222 28 (9.06%)
V CIP, SXT 0.222 3 (0.97%)
VI CIP, LEV 0.222 14 (4.53%)
VII IMI, MER, SXT 0.333 12 (3.88%)
VIII IMI, MER, GEN 0.333 18 (5.83%)
IX CIP, LEV, SXT 0.333 18 (5.83%)
X CIP, LEV, MER 0.333 6 (1.94%)
XI CIP, LEV, IMI 0.333 10 (3.24%)
XII CIP, LEV, GEN 0.333 9 (2.91%)
XIII CIP, LEV, IMI, MER 0.444 20 (6.47%)
XIV CIP, LEV, GEN, AMI, SXT 0.555
MDR (42.72%; n = 132)
29 (9.40%)
XV CIP, LEV, GEN, AMI, SXT, TIG 0.666 20 (6.47%)
XVI CIP, LEV, IMI, MER, GEN, SXT 0.666 12 (3.88%)
XVII CIP, LEV, IMI, MER, GEN, TIG 0.666 10 (3.24%)
XVIII CIP, LEV, IMI, MER, GEN, AMI, SXT 0.777 47 (15.21%)
XIX CIP, LEV, IMI, MER, GEN, AMI, SXT, TIG 0.888 7 (2.27%)
XX CIP, LEV, IMI, MER, GEN, AMI, SXT, COL 0.888 5 (1.62%)
XXI CIP, LEV, IMI, MER, GEN, AMI, SXT, TIG, COL 1.000 2 (0.65%)
* based on the criteria of Magiorakos et al. [27].
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3.2. Detection of Carbapenemase-Production and Efflux Pump-Overexpression Using
Phenotypic Methods
To identify the contribution of various resistance mechanisms in the drug resistance of
the relevant A. baumannii isolates, phenotypic tests were utilized. The modified Hodge test
(MHT) was used to detect for the production of carbapenemases: overall, 22.65% (n = 70)
of tested isolates (i.e., 42.94% of isolates resistant to either IMI, MER, or both) were positive
for the phenotypic detection of carbapenemases in the MHT assay. MBL production was
observed in 9.06% (n = 28) of the tested isolates (i.e., 17.18% of isolates resistant to either
IMI, MER, or both) using the imipenem/EDTA combined disk test (CDT). Overexpression
of the RND efflux pumps (based on the results of the PaβN screening agar) had significant
effects on the MICs of MER in 14.24% (n = 44; i.e., 27.67% of isolates resistant to MER),
while this was 6.05% in the case of GEN (n = 19; i.e., 10.11% of isolates resistant to GEN)
and 27.51% in the case of CIP (n = 85; i.e., 38.64% of isolates resistant to CIP), which was
demonstrated by the four-fold decrease in MICs detected in the presence of the efflux
inhibitor compound. In the case of n = 17 and n = 8 isolates, simultaneous positivity of
the efflux pump-overexpression-MHT test and efflux pump-overexpression-CDT test was
detected, respectively.
3.3. Biofilm Formation among MDR and Non-MDR A. baumannii Isolates
Biofilm formation assays were carried out in a microtiter plate-based platform, using
CV staining. The OD570 values for the negative control (clinical isolate no. 59738) and the
positive control (ATCC 19606) were 0.091 ± 0.008 and 0.388 ± 0.051, respectively. Therefore,
the Odc value was set at 0.115, and the classification breakpoints were the following: non-
biofilm producer: OD ≤ 0.115, weak biofilm producer: 0.230 ≥ OD > 0.115, medium biofilm
producer: 0.460 ≥ OD > 0.230, and strong biofilm producer: OD > 0.460. Based on this,
9.39% (n = 29), 12.29% (n = 38), 22.97% (n = 71), and 55.35% (n = 170) were non-biofilm
producers, and weak, moderate, and strong biofilm producers, respectively; OD570 values
ranged between 0.022 ± 0.003 and 1.192 ± 0.086, with the median value being 0.501 (0.466,
0.534). In addition, 62.14% (n = 192) of isolates were more potent biofilm producers than the
ATCC 19606 strain. A numerical but statistically not significant difference was identified
between the MDR and non-MDR isolates regarding their biofilm-forming capacity overall
(MDR: 0.495 ± 0.309 vs. non-MDR: 0.545 ± 0.283; p = 0.072) (Figure 1). During the analysis
for individual associations between antibiotic resistance and biofilm propensity (where
COL was excluded, due to the low number of resistant isolates), concordance was seen
with the overall results, as no significant differences were shown for CIP (susceptible
[S]: 0.556 ± 0.329 vs. resistant [R]: 0.499 ± 0.308; p = 0.55), LEV (S: 0.523 ± 0.299 vs. R:
0.508 ± 0.276; p = 0.63), SXT (S: 0.555 ± 0.262 vs. R: 0.492 ± 0.306; p = 0.28), GEN (S:
0.537 ± 0.329 vs. R: 0.463 ± 0.302; p = 0.66), AMI (S: 0.560 ± 0.283 vs. R: 0.481 ± 0.330;
p = 0.99), TIG (S: 0.559 ± 0.349 vs. R: 0.471 ± 0.279; p = 0.81), IMI (S: 0.605 ± 0.283 vs. R:
0.538 ± 0.331; p = 0.63), and MER (S: 0.600 ± 0.315 vs. R: 0.538 ± 0.326; p = 0.68). While,
based on numerical trends, MER-resistant isolates were the strongest biofilm producers, the
ANOVA did not reveal significant differences (p = 0.067) between the biofilm production
among antibiotic-resistant isolates.
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In A. bauma nii, Ambler Class D (OXA-type carbapenemases: the species possesses an
intrinsic β-lactamase gene (blaOXA-51-like), which is often used for the identification of this
species), and Cl ss B (metallo-β-l ctamases; MBLs) are the most prevalent, while Class A
(serine β-lactamases) enzymes have also been describe on occasion [35]. The relevance of
these enzymes has increased in recent years (either alone or co-existing with OXA-type
enzymes) and represents an important therapeutic conundrum, as there are currently
no licensed inhibitors for their inhibition in clinical use [36]. As there is limited clini-
cal experience with novel, innovative β-lactam-type drugs (e.g., ceftazidime/avibactam,
imipenem/relebactam, meropenem/vaborbactam, and cefiderocol) for Acinetobacter in-
fections, non-β-lactam-type drugs often need to be administered [37]. For a number of
years, colistin was the drug-of-choice for CR-AB infections, due to the fact that Acinetobacter
spp. are still largely susceptible to this drug; however, resistance rates have been steadily
emerging in the recent years [38]. Other potentially useful drugs include tigecycline (where
susceptibility data allow for it) and novel tetracycline derivatives (eravacycline and omada-
cycline), plazomicin and delafloxacin, or high-dose combinations of existing drugs, such as
meropenem-colistin [26,37]. Nevertheless, it must be noted that many of the above-listed
antimicrobials may have debilitating adverse events and may not be suitable for a wide
array of patients. Based on the findings of a systematic review, acquiring the MDR status
in Acinetobacter spp. is most often due to resistance to aminoglycosides and carbapenems,
while XDR and PDR (pan-drug resistance) are often associated with resistance to colistin,
tigecycline, and other ancillary antibiotics [38]. As a consequence of the Severe Acute
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic and the associated disease
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(COVID-19), patients undergoing mechanical ventilation have soared; these patients are
particularly at risk for nosocomial Acinetobacter spp. infections, due to the introduction of
assisted ventilation and the preceding viral infection, which predisposes patients to bacte-
rial superinfections. Rapid increases are expected in the resistance rates of Acinetobacter
spp. and other bacterial pathogens, associated with the extensive and prophylactic use of
antimicrobials in relation with COVID-19 [39].
As a part of our study, a large pool (n = 309) of A. baumannii isolates from diverse
geographical and clinical origins were subjected to phenotypic assays to characterize the
possible correlation between biofilm-forming capacity and antimicrobial resistance in these
isolates. In our pool of isolates, resistance rates were highest for the fluoroquinolones
(~70%), while >42% were classified as MDR. Over 20% of isolates were positive for car-
bapenemase production (although our methods may not have enough sensitivity to reli-
ably detect all carbapenemases relevant in A. baumannii [29]), ~9% were positive for MBL
production, while in ~14%, carbapenem nonsusceptibility was affected by efflux pump
overexpression (based on the phenotypic tests applied). The levels of MDR in the isolates
were similar to the MDR rates in Central Europe; however, carbapenem-resistance rates
were >50% [9]. Our results have highlighted that—based on susceptibility alone—colistin
and tigecycline may still be optimal treatment choices for A. baumannii. A limitation of our
study is that many additional antibiotics were not tested to establish the potential XDR or
PDR status of the isolates [38].
The majority of isolates (62.14% overall) were strong biofilm producers, both in the
MDR and non-MDR groups; our tests conducted did not verify a significant difference
in biofilm formation based on the susceptibilities of the relevant isolates to the tested
antimicrobials. Based on the reports from the recent literature, the rate of biofilm formation
in A. baumannii is around 75–100%, which is similar to rates observed in NFGNB, and
significantly higher than those of members of the Enterobacterales and Gram-positive
bacteria (0–40%); additionally, many studies have shown that environmental Acinetobacter
isolates often produce more robust biofilms—probably with the aim of being resistant to
desiccation—compared to isolates from clinical origins [17,40]. Zeighami et al. reported
on the virulence characteristics of one hundred Acinetobacter spp. isolated from ICU
patients: 91% of isolates were XDR, while 32% were resistant to all antibiotics tested, and
the presence of class I and class II integrons was revealed in 67% and 10%; all isolates
(100%) were either moderate or strong biofilm producers, with 100%, 98%, 95%, 92%,
and 81% with carriage of csuE, pgaB, epsA, ptk, bfmS, and the ompA biofilm-related genes,
respectively [41]. The study of Hassan et al. involved n = 74 A. baumannii isolates (both
from clinical material and from environmental origins, identified by the presence of the
blaOXA-51-like carbapenemase), which were assessed for the biofilm formation by three
independent methods (CV tube method, CV tissue microtiter plates, and Congo Red Agar)
in juxtaposition with their resistance. The majority of clinical isolates (>90%) were resistant
to ciprofloxacin, gentamicin, and carbapenems, although no carbapenemase genes were
found during molecular testing. In addition, 64.86% of isolates were classified as moderate
and strong biofilm producers; biofilm formation was stronger in isolates susceptible to
ciprofloxacin, gentamicin, and imipenem/meropenem [42]. Qi et al. included n = 272
A. baumannii isolates from various general hospitals in China, which had resistance rates
to ciprofloxacin, ceftazidime, trimethoprim/sulfamethoxazole, imipenem, amikacin, and
polymyxin B of 65.8%, 61.0%, 59.9%, 59.2%, 46.0%, and 3.7%, respectively. In addition,
>72% classified as either MDR or XDR, and 23% were classified as strong biofilm producers,
with non-MDR isolates producing a significantly more robust biofilm (this association was
also verified for susceptibility to all individual antibiotics, apart from polymyxin B). Pulse-
field gel electrophoresis (PFGE) analyses have revealed that the majority of nonsusceptible
isolates—which were weak biofilm producers—belonged to the same eight main PFGE
clusters [43].
Thummeepak et al. included n = 225 A. baumannii strains to perform phenotypic and
molecular testing, during which 86.2% presented as MDR and 76.9% were biofilm produc-
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ers; the presence of virulence and biofilm-related genes (epsA, bap, ompA, and bfmS) showed
significant association with the MDR phenotype in these isolates; additionally, a higher
number of biofilm producers were detected among gentamicin-resistant A. baumannii [44].
Greene et al. studied n = 145 clinical and environmental A. baumannii isolates for their
biofilm-forming capacity: using cell death due to desiccation as an indicator, they found
that non-MDR isolates were 2.7-times more susceptible to drying damage than the MDR
isolates were [45]. Using A. baumannii clinical isolates and the ATCC 17978 reference strain
as model organisms, Mayer et al. identified that operating quorum sensing (QS) systems
are needed for functional motility and biofilm formation in vitro; their study highlighted
that extracellular DNA is critical for the integrity of robust biofilms, in addition to showing
that biofilm formation did not correlate with the antibiotic resistance of said isolates [46]. In
addition, Selasi et al. noted that biofilm formation positively correlated with the expression
level of many relevant virulence factors, such as surface proteins, pili, and the production
of poly-β-(1-6)-N-acetylglucosamine (PNAG) and acyl-homoserine lactone (AHL) signal
molecules [47].
Several authors have aimed to propose a definite genetic link between the propen-
sity to form biofilms and antimicrobial resistance in A. baumannii [17]. In the study of
Aziz et al., A. baumannii isolates—which carried the extended spectrum β-lactamase
blaPER-1—produced a significantly more robust biofilm than the gene-deficient bacteria;
their results showed that blaPER-1-positive isolates more efficiently adhered to epithelial
cells in in vitro settings, and this attribute may be relevant in the early stages of biofilm pro-
duction [48]. On the other hand, Gallant et al. showed contrasting findings for P. aeruginosa,
where isolates presenting with and expressing the β-lactamase gene blaTEM-1 had limited
ability to form biofilms, which was suggested to be a consequence of the low adhesive po-
tential of these strains [49]. The biofilm-associated protein (Bap) is a cell surface protein in
Acinetobacter spp.—homologous with the Bap protein found in Staphylococcus spp.—which
has important roles to surface attachment and biofilm maturation. In the context of an-
tibiotic resistance, it has been suggested that interactions of Bap and the outer membrane
protein OmpA, which functions as the major porin A. baumannii, may have relevance
in biofilm-forming capacity; namely, porin-deficient strains may show less pronounced
biofilm production [18]. Our study emphasizes the need for additional experiments to
assess the role biofilms have in the pathogenesis of A. baumannii infections.
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